Novartis India share price
You have to be logged in to add this to Watchlist.- ₹769.10(-0.21%)March 13, 2025 15:56:06 PM IST
- NSE
- BSE
- Vol : 7.64K (NSE + BSE)Last 20 day avg : 12.43 K
Novartis India is trading -0.21% lower at Rs 769.10 as compared to its last closing price. Novartis India has been trading in the price range of 777.90 & 768.00. Novartis India has given -16.38% in this year & -4.42% in the last 5 days. Novartis India has TTM P/E ratio 26.32 as compared to the sector P/E of 28.29.The company posted a net profit of 25.45 Crores in its last quarter.Listed peers of Novartis India include Indoco Remedies (-0.62%), Bajaj Healthcare (-0.90%), Novartis India (-0.21%).The Mutual Fund holding in Novartis India was at -% in . The MF holding has - from the last quarter. The FII holding in Novartis India was at 0.19% in 31 Dec 2024. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Mar 16, 2025, 06:49 AM UTC
- Dividend YieldHigher than industry3.25Annual dividends as a percentage of the stock price.
- P/BHigher than historical values2.55The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values22.01Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.71Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.01The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 10.01% from Rs 93.00 crore to Rs 84.54 crore, year-on-year
The company's profit declined by 4.22% year-on-year during the December quarter, dropping from Rs 26.57 crore to Rs 25.45 crore- The debt to equity of the company is lower than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 840.63
- R2
- 878.82
- R3
- 915.13
- S1
- 766.13
- S2
- 729.82
- S3
- 691.63
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Indoco Remedies | Bearish | 218.00 | -0.62 | 2,000.61 | 22.30 | 1.82 | 0.69 | 32.81 |
| Bajaj Healthcare | Bullish | 635.95 | -0.90 | 2,009.60 | 168.51 | 6.27 | 0.16 | 14.06 |
| Novartis India | Bearish | 769.10 | -0.21 | 1,898.97 | 23.41 | 2.55 | 3.25 | 0.68 |
| Windlas Biotech | Neutral | 885.55 | -0.34 | 1,861.33 | 32.04 | 4.13 | 0.62 | 0.45 |
| Amrutanjan Health Care | Bearish | 586.05 | -0.60 | 1,713.06 | 37.65 | 5.9 | 0.78 | 0.48 |
- Promoter(s) holds a high stake in the company at 70.68%
- FIIs are invested in this company
- FIIs holding is constant over the last quarter at 0.19%
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-01-28 | Quarterly Results |
| 2024-10-25 | Quarterly Results |
| 2024-05-10 | Audited Results & Final Dividend |
| 2024-01-25 | Quarterly Results |
| 2023-10-27 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE234A01025
- BSE Code500672
- NSE CodeNOVARTIND
Novartis India is trading at 769.10 as on Thu Mar 13 2025 10:26:06. This is -0.21% lower as compared to its previous closing price of 770.70.
The market capitalization of Novartis India is 1898.97 Cr as on Thu Mar 13 2025 10:26:06.
The 52 wk high for Novartis India is 1248.00 whereas the 52 wk low is 768.00
Novartis India can be analyzed on the following key metrics -
- TTM P/E: 26.32
- Sector P/E: 28.29
- Dividend Yield: 3.25%
- D/E ratio: -
Novartis India reported a net profit of 85.19 Cr in 2024.